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Abstract: There is controversy about the relationship between ACE I/D polymorphism and health.
Seventy-four healthy adults (n = 28 women; 22.5 ± 4.2 years) participated in this cross-sectional
study aimed at determining the influence of ACE I/D polymorphism, ascertained by polymerase
chain reaction, on cardiometabolic risk (i.e., waist circumference, body fat, blood pressure (BP),
glucose, triglycerides, and inflammatory markers), maximal fat oxidation (MFO), cardiorespira-
tory fitness (maximal oxygen uptake), physical activity and diet. Our results showed differences
by ACE I/D polymorphism in systolic BP (DD: 116.4 ± 11.8 mmHg; ID: 116.7 ± 6.3 mmHg; II:
109.4 ± 12.3 mmHg, p = 0.035) and body fat (DD: 27.3 ± 10.8%; ID: 22.6 ± 9.7%; II: 19.3 ± 7.1%,
p = 0.030). Interestingly, a genotype*sex interaction in relativized MFO by lean mass (p = 0.048) was
found. The DD polymorphism had higher MFO values than ID/II polymorphisms in men (8.4 ± 3.0
vs. 6.5 ± 2.9 mg/kg/min), while the ID/II polymorphisms showed higher R-MFO values than DD
polymorphism in women (6.6 ± 2.3 vs. 7.6 ± 2.6 mg/kg/min). In conclusion, ACE I/D polymor-
phism is apparently associated with adiposity and BP, where a protective effect can be attributed
to the II genotype, but not with cardiorespiratory fitness, diet and physical activity. Moreover, our
study highlighted that there is a sexual dimorphism in the influence of ACE I/D gene polymorphism
on MFO.
Keywords: genetic association studies; heart diseases; lipid metabolism; healthy lifestyle; angiotensin-
converting enzyme; obesity
1. Introduction
Cardiovascular diseases (CVD) are one of the main causes of mortality in developed
countries [1], thus, cardiometabolic risk (CMR) factors should be analyzed in different
populations, including hypertension, dietary risk, adiposity, hyperglycemia and low physi-
cal fitness [2]. Furthermore, it has been shown that inflammatory markers can be equal
to or even more useful than traditional risk factors in predicting future cardiometabolic
events [3]. Nonetheless, the study of the genetic component of these diseases is essential,
since in most cases the origin of CVD is multifactorial. Thus, the study of heritage and
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its relationship with CMR factors could help clarify the causes of CVD attending to the
influence of relevant factors including biological sex [4].
In this line, a human angiotensin I-converting enzyme (ACE) gene insertion/deletion
(I/D) polymorphism, located on chromosome 17q23, is associated with CVD [5,6]. The
ACE I/D polymorphism consists in the presence (insertion, I) or absence (deletion, D) of a
287 base pair fragment in intron 16 of ACE gene [7]. The ACE gene produces the protein
ACE, which converts angiotensin (AngI) into angiotensin II (AngII), a potent vasoactive
peptide that leads to effects mainly hypertensive, highlighting its role in the physiology
of blood vessels and inflammation [5,8]. Indeed, higher plasma levels of ACE have been
reported when the D allele was present [5], accordingly, the ACE DD genotype has been
established as an independent risk factor of CVD and hypertension [6,9]. Similarly, a recent
meta-analysis [10] has shown a higher risk of hypertrophic cardiomyopathy in the DD
genotype than in the II genotype; therefore, a protective effect against CVD risk can be
attributed to the II genotype.
Moreover, the cardiorespiratory fitness (CRF), expressed as maximal oxygen uptake
(VO2max), has been established as a main preventive factor of CVD [1] and there seems to
be a tendency for higher VO2max with the ACE II genotype [11], although with inconsistent
associations in the literature [12]. Regarding the aerobic capacity and health, the maximal
fat oxidation (MFO) capacity has been posed as a key indicator of metabolic flexibility [13]
and, consequently, a lower CMR [14]. Nevertheless, only one study has investigated
the influence of ACE I/D polymorphism on resting fat oxidation [15] and, to our best
knowledge, there are no previous studies on the relationship between ACE gene I/D
polymorphism and MFO despite its relevance to CVD and weight management.
The analysis of the genetic influence of the ACE I/D polymorphism on CMR and
related outcomes should also consider age, physical activity and diet, among others [16];
moreover, sex differences can mediate the associations [4,16]. It should be note that most of
the articles include a sample with a mean age over 55 years [10], therefore, the analysis in
other ranges of age could be interesting.
Thus, the aims of the present study were (i) to determine the influence of ACE gene
I/D polymorphism on CMR, MFO, CRF, diet and physical activity in young adults and (ii)
to ascertain whether there are sex differences in these relationships.
2. Materials and Methods
2.1. Design
In this cross-sectional study from the “NutAF” project [14,17], the ACE gene I/D
polymorphism was measured in a young adult population from Cadiz (Spain), and its
possible influence with CMR and related outcomes was analyzed.
In this sense, CMR was determined considering waist circumference, body fat per-
centage, systolic (SBP) and diastolic (DBP) blood pressure, blood glucose, triglycerides,
and inflammatory cytokines (TNF-α and IL-6); moreover, MFO and CRF (VO2max) were
analyzed. All these measurements were performed in one day, in fasting conditions (>8 h),
and in the morning (from 8:00 until 11:30 am). Additionally, the week before measurements,
physical activity and diet were registered.
The study was approved by the Ethical Committee of the Hospital Puerta del Mar
(Cadiz, Spain), in accordance with the Declaration of Helsinki. All tests were performed
in the Laboratory of Physical Activity and Exercise of the University of Cadiz (Puerto
Real, Spain).
2.2. Subjects
A total of 74 subjects (28 females) participated in the study and, apart from being
obese, all subjects were apparently healthy but with different metabolic profiles. The
characteristics of the participants are shown in Table 1. The inclusion criteria were: being
between 18 and 45 years old, having a stable body mass (±2 kg) during the last 6 months
and having a Body Mass Index (BMI) between 18.5 and 40 kg m−2. The exclusion criteria
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were: having made a weight-loss diet or a specific diet different to the regular one during
the last 6 months or suffering any illness or injury that prevented physical exercise. Written
informed consent was obtained by all participants after being informed about the nature of
the study, its protocol and possible risks arising from the measurements.
Table 1. General characteristics of total sample and differences between men and women.
Total Men Women p d
Age (years) 22.46 ± 4.21 22.23 ± 3.59 22.88 ± 5.21 0.526 −0.15
Height (cm) 172.06 ± 8.85 176.68 ± 6.32 163.52 ± 6.07 <0.001 2.11
Body Mass (kg) 74.97 ± 15.74 77.84 ± 14.43 69.69 ± 16.95 0.033 0.53
Lean body mass (kg) 54.38 ± 8.92 59.26 ± 6.41 45.37 ± 5.00 <0.001 2.35
Body fat (%) 21.97 ± 9.34 18.28 ± 7.08 28.77 ± 9.30 <0.001 −1.31
Body Mass Index (kg ·m−2) 25.36 ± 5.48 24.87 ± 3.87 26.28 ± 7.64 0.292 −0.25
Waist circumference (cm) 82.27 ± 14.33 83.73 ± 12.19 79.92 ± 17.24 0.289 0.27
Total MVPA (min/week) 501.96 ± 166.99 480.95 ± 146.25 539.14 ± 196.08 0.157 −0.35
Energy balance (kcal/day) 280.26 ± 1008.83 303.99 ± 1164.61 236.45 ± 647.19 0.785 0.07
MD adherence (0–14 range) 6.99 ± 1.78 7.21 ± 1.92 6.58 ± 1.45 0.146 0.36
Systolic Blood Pressure (mmHg) 114.20 ± 10.26 116.70 ± 7.88 109.52 ± 12.56 0.004 0.73
Diastolic Blood Pressure (mmHg) 68.46 ± 9.88 66.96 ± 9.00 71.27 ± 10.98 0.078 −0.44
Blood pressure recovery (ratio) 0.82 ± 0.30 0.79 ± 0.34 0.88 ± 0.19 0.242 −0.29
Plasma glucose (mg/dL) 101.76 ± 10.02 103.90 ± 9.55 97.83 ± 9.84 0.016 0.63
Plasma triglycerides (mg/dL) 69.06 ± 24.83 70.28 ± 24.52 66.84 ± 25.77 0.589 0.14
Tumor necrosis factor-α (pg/mL) 8467.15 ± 7574.43 9934.35 ± 8443.06 5960.69 ± 5027.59 0.040 0.54
Interleukin-6 (pg/mL) 473.44 ± 338.41 504.84 ± 370.25 408.79 ± 259.09 0.342 0.29
BM VO2max (mL · kg−1 ·min−1) 42.10 ± 11.49 46.07 ± 10.11 34.93 ± 10.42 <0.001 1.09
LM VO2max (mL · kg−1 ·min−1) 18.90 ± 4.54 18.80 ± 4.84 19.09 ± 4.00 0.789 −0.07
Absolute MFO (g ·min−1) 0.38 ± 0.15 0.40 ± 0.17 0.32 ± 0.11 0.029 0.55
R-MFO (mg ·kg−1 ·min−1) 7.03 ± 2.86 6.95 ± 3.05 7.16 ± 2.57 0.768 −0.07
Clustered CMR (Z-score) 0.32 ± 3.29 0.50 ± 3.15 0.04 ± 3.56 0.605 0.14
INFLAM-Clustered CMR (Z-score) −0.03 ± 3.14 0.10 ± 3.39 −0.24 ± 2.79 0.732 0.11
N 74 46 28
Sex differences (p < 0.05) in the Student t test appear in bold. Values are expressed as mean ± standard deviation. Abbreviations: d, Cohen’s
d; MVPA, Moderate to vigorous physical activity; MD, Mediterranean diet; BM, Body mass; LM, Lean mass; VO2max, Maximal oxygen
uptake; R-MFO, Maximal fat oxidation rate relativized to lean mass; CMR, Cardiometabolic risk; INFLAM-Clustered CMR, Cluster of CMR
which includes TNF-α and IL-6.
2.3. Procedure
Initially, physical activity and diet were analyzed during the week before measure-
ments, thus, participants were asked to maintain lifestyles during this period.
On the day of measurements, fasting blood samples and laboratory tests were per-
formed. Participants were instructed to avoid intense physical activity the day before, to
maintain their usual diet/hydration, and to avoid the intake of alcohol and caffeine the
day before.
Firstly, heart rate and blood pressure were registered. Secondly, blood samples were
taken in order to later determine the ACE gene I/D polymorphism, and those plasma
markers used to estimate CMR, i.e., glucose, triglycerides, tumor necrosis factor-α (TNF-α),
and interleukin-6 (IL-6). After that, anthropometric and body composition measurements
were performed, then, a face mask was placed for the analysis of basal metabolism and the
exercise protocol.
2.4. Physical Activity
The physical activity of the participants was objectively measured through accelerom-
etry (GT3X+, Actigraph TM, LLC, Fort Walton Beach, FL, USA) for 7 consecutive days
before the laboratory tests. The accelerometer was attached tightly in the hip, on the back
side, with the notch faced upwards, and the participants were instructed to use it during
waking hours and remove it during water-based activities. Only the participants wearing
the accelerometers for ≥10 h/day during at least 4 days (including at least 1 weekend
day) were included in the final analyses. Total physical activity was calculated to estimate
energy balance according to the dietary intake. In addition, moderate to vigorous physical
Int. J. Environ. Res. Public Health 2021, 18, 3443 4 of 12
activity (MVPA) was calculated, considered any activity from moderate to very vigorous
(over 2691 counts/min).
2.5. Dietary Assessment
Dietary intake was estimated through a 5-day dietary record the week before the
laboratory tests, including three consecutive weekdays and both days of the weekend. All
the participants were instructed to correctly fill it, recording each food by the weighing
method. DIAL software (version 1.19) was used to estimate dietary energy intake. The
energy balance was obtained subtracting the daily caloric expenditure (obtained from the
sum of the basal metabolism and the caloric expenditure of physical activity) from the
dietary energy intake. Likewise, dietary patterns were assessed concerning adherence to
Mediterranean diet by using a previously validated questionnaire of 14 items [18].
2.6. Heart Rate and Blood Pressure Measurements
For the heart rate and blood pressure measurements, the participants were sitting in
a chair, relaxed and with their feet on the floor. After 10 min, measurements of systolic
blood pressure (SBP), diastolic blood pressure (DBP) in the non-dominant arm were taken
with an Omron M3 digital monitor (HEM-7051-E, Kyoto, Japan). The average of three
measurements, taken one minute apart, was used for analyses. Heart rate was continuously
measured (at rest and during exercise) with a Polar Team 2 (Polar Electro Inc., Lake Success,
NY, USA). Moreover, blood pressure recovery after exercise was taken into account using a
third minute of recovery SBP to peak exercise SBP ratio [19].
2.7. Blood Extraction
Blood sample was taken from the antecubital vein, after 10 min in sitting position, by
a nurse. Blood samples were collected in tubes containing EDTA and centrifuged to obtain
plasma at 2500 rpm for 15 min at 4 ◦C. Clotted and hemolysed samples were discarded.
Plasma was stored at −80 ◦C for subsequent analysis.
2.8. Genomic Typing of the ACE Gene I/D Polymorphism
Genomic Deoxyribonucleic acid (DNA) was extracted from peripheral blood anti-
coagulated with EDTA using a standard phenol/chloroform procedure followed by al-
cohol precipitation. A polymerase chain reaction (PCR) amplification was performed
using a StepOne™ Real-Time PCR System (Life Technologies, Foster City, CA, USA).
Allelic discrimination analysis for the ACE gene I/D polymorphism was performed
by PCR followed by electrophoresis on a 1.5% agarose gel containing ethidium bro-
mide [20]. The primers used were: 5′-CTGGAGAGCCACTCCCATCCTTTCT and 5′-
GACGTGGCCATCACATTCGTCAGAT. The amplified fragments were a 190 bp product
for allele D (allele without insertion) and a 490 bp product for allele I (allele with insertion).
In order to avoid the diagnosis of false negatives (ID heterozygotes misclassified as DD
homozygotes), a second PCR reaction was performed in all samples initially classified as
DD [21], with these insertion-specific primer pair: 5′-TGGGACCACAGCGCCCGCCACTAC
and 5′-TCGCCAGCCCTCCCATGCCCATAA. Only the allele I produced a 335 bp fragment,
identified on a 1.5% agarose gel stained with ethidium bromide performed in all of the
samples initially classified as DD with these.
2.9. Plasma Biochemical Parameters
At the time of the analysis, samples were thawed on ice and then pipetted in duplicates
of 10 µL into the microplates with 200 µL of the specific reagent from each commercial kit.
In all plates, pattern curves of known concentrations of each parameter in question were
added, in order to identify the absorbance data. For the analysis, the instructions of the
manufacturer Spinreact (Spinreact SA, Sant Esteve d’en Bas, Girona, Spain) were followed
and, by adapting the measurements to 96-well microplates, the metabolic parameters
were analyzed in plasma including the levels of blood glucose (Glucose-HK Ref. 1001200)
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and triglycerides (TAG: Ref. 1001311). Subsequently, the microplates were introduced
in a BIO-TEK PowerWaveTM 340 microplate reader and the absorbance readings were
processed with the BIO-TEK KC JuniorTM program (Bio-Tek Instruments Inc., Winooski,
VT, USA). Two inflammatory markers, TNF-α and IL-6, were determined by Bio-Plex 200
Systems with Bio-Plex ProTM Human Cytokine Assay kits (Bio-Rad Laboratories Inc.,
Shanghai, China).
2.10. Anthropometry and Body Composition
Height was measured in a standing position, after normal expiration, using a height
rod (SECA 225, Hamburg, Germany; range of 60 to 200 cm, precision of 1 mm). Waist
circumference was measured using a plastic anthropometric tape (SECA 201, Hamburg,
Germany; range of 0 to 205 cm, precision of 1 mm) at the midpoint between the costal
margin and iliac crest in the mid-axillary line in standing position at the end of a gentle
expiration. The measurements were performed twice, and the average values were used for
the analysis. Body mass (kg), body fat (kg and %) and lean mass (kg and %) were evaluated
using a multi-frequency bioimpedance of 8 electrodes (TANITA-MC780MA, Barcelona,
Spain). The subjects wore light clothing and adopted a specific posture according to the
manufacturer’s instructions. All participants had to urinate before the test, which should
be done without any metallic object in the body that could alter the results. BMI was
determined as body mass (kg) divided by the square of height (m−2).
2.11. Basal Metabolism
Oxygen uptake (VO2) and carbon dioxide production (VCO2) were registered in
resting conditions lying on a bed in a supine position for 30 min for calculating RER
(Respiratory Exchange Ratio) and fat oxidation in a conditioned room (21 ± 1 ◦C, 50 ± 2%
Relative Humidity). A mask was placed on the subject’s face to collect gas samples. An
indirect circuit gas analyzer, Jaeger MasterScreen CPX® (CareFusion, San Diego, CA, USA)
was used to register indirect calorimetry data. Calibrations were daily performed before
each measurement. During the test, the gas analyzer values were captured breath-by-
breathe and averaged every 20 s. For the analysis of these variables, the first 5 min of the
evaluation were eliminated and a stable period of 5 min was selected with a coefficient of
variation for VO2 and VCO2 lower than 15%. The average values of VO2 and VCO2, in the
selected time interval, were used to calculate the basal metabolism (kcal) by an indirect
equation proposed by Frayn [22].
2.12. Maximal Fat Oxidation (MFO) and Cardiorespiratory Fitness (VO2max)
An incremental protocol in cycle ergometer (Lode Excalibur, Groningen, The Nether-
lands) was designed from the standardized protocol [23], with two consecutive phases
to determine MFO and maximal oxygen uptake (VO2max). The first phase, for the deter-
mination of MFO, consisted of 3-min steps with 15 W increments in overweight/obese
subjects and 30 W in subjects with normal weight, with a maintained pedaling rate be-
tween 60–80 rpm. This phase was interrupted when RER ≥ 1. After a brief pause (between
3 and 5 min), the second phase to detect VO2max was initiated. This phase began at the
load at which phase 1 ended, and continued with 1-min steps increasing at the same load
rate as in phase 1, with equal cadence. This phase ended when the participant reached
exhaustion. The protocol was considered maximum when the VO2 reached a plateau, the
theoretical maximal heart rate was reached and when RER ≥ 1.10. When the aforemen-
tioned maximality criteria were not met, the VO2peak was used. RER, VO2 and VCO2
were measured by indirect calorimetry (Jaeger MasterScreen CPX®). To calculate the fat
oxidation in the different steps of the protocol, the average values of VO2 and VCO2 were
used in the last 60 s of each step of the test, applying the Frayn equation [22]. Similarly, the
average value of VO2 was used to determine the % VO2max reached in each step. With the
values obtained from fat oxidation and % VO2max in each step, a polynomial curve that
best fits the results of the present analysis were drawn for each participant.
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2.13. Statistical Analysis
Chi-squared (χ2) test was used to verify the Hardy-Weinberg equilibrium and to
describe both the genotypic and allelic frequencies. Normality of distribution and homo-
geneity of variance were contrasted by applying the Kolmogorov-Smirnov and Levene tests.
Descriptive statistics were calculated and expressed as mean ± standard devia-
tion (SD), comparison between sexes were determined through a Student t test. All out-
comes were separately analyzed, additionally, two CMR clusters were calculated. A CMR
cluster according to sex was created by using standardized values (Z-score) [(value −
mean)/standard deviation] of waist circumference, body fat percentage, SBP, DBP, blood
glucose and triglycerides. Furthermore, a second CMR cluster was created including the
inflammatory cytokines TNF-α and IL-6 to the aforementioned cluster model.
The differences between the groups according to the ACE gene I/D polymorphism
(DD, ID and II) in CMR, MFO, CRF, physical activity and diet were analyzed by applying a
1-way analysis of variance (ANOVA) followed by the Bonferroni post-hoc comparisons.
Moreover, a recessive model with two groups (DD vs. ID/II) was established and a Student
t test was used to determine differences between groups.
The possible interaction of sex with the ACE gene I/D polymorphism in the analyzed
variables was investigated through a 2-way ANOVA, followed by the Bonferroni post-hoc
comparisons.
Effect size statistics were calculated, with Cohen’s d for Student t test, η2 for 1-way
ANOVA, and ηp2 for 2-way ANOVA. The level of significance was set at p≤ 0.05. IBM SPSS
Statistics 22 software (SPSS Inc., Chicago, IL, USA) was used for the statistical analysis.
3. Results
The Hardy-Weinberg equilibrium (HWE) test showed that χ2 = 0.801, p = 0.371,
suggesting that the population is consistent with HWE, and confirming that the allele
types were randomly sampled. The expected frequencies were DD (p = 0.2849) n = 21.1,
ID (p = 0.4977) n = 36.8, and II (p = 0.2176) n = 16.1. The distribution of ACE genotype
frequencies was 31% for DD, 45% for ID, and 24% for II.
Regarding descriptive characteristics of the participants (Table 1), as it was expected,
men had higher height, body mass and lean body mass, with lower body fat percentage,
than women. Moreover, men presented significantly higher SBP, with a trend in DBP
(p < 0.10), higher blood glucose and TNF-α, compared with women. Men reported higher
values in VO2max relativized to body mass and absolute MFO than women; however, when
VO2max and MFO were relativized to lean body mass showed no differences between sexes.
The differences between ACE gene variants (DD, ID and II) on body composition,
physical activity, diet, biochemical parameters, CRF, MFO and CMR of the participants are
presented in Table 2. The II group presented lower body fat percentage than the DD group
and lower SBP than DD and ID groups. In Table 3, the differences according to the recesive
model of alleles (DD vs. ID/II) are presented, where the DD genotype showed higher body
fat than the ID/II genotype, also with a similar trend in BMI and the CMR cluster with
inflammatory cytokines.
Table 2. Differences in the analyzed outcomes between the three ACE gene I/D polymorphism groups.
DD ID II p η2
Number of men/women 11/12 23/10 12/6 - -
Age (years) 23.57 ± 5.29 22.33 ± 4.29 21.83 ± 2.07 0.390 0.03
Height (cm) 170.67 ± 10.32 173.09 ± 8.31 172.34 ± 7.12 0.593 0.01
Body Mass (kg) 79.71 ± 17.44 76.94 ± 16.31 70.77 ± 11.81 0.194 0.05
Lean body mass (kg) 53.66 ± 8.20 55.37 ± 9.80 53.51 ± 7.90 0.694 0.01
Body fat (%) 27.29 ± 10.82 22.55 ± 9.72 19.31 ± 7.13 0.030 * 0.09
Body Mass Index (kg ·m−2) 27.64 ± 7.38 25.63 ± 4.89 23.78 ± 3.33 0.088 0.07
Waist circumference (cm) 86.78 ± 16.89 84.01 ± 14.81 78.26 ± 9.77 0.223 0.05
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Table 2. Cont.
DD ID II p η2
Total MVPA (min/week) 501.55 ± 171.02 469.59 ± 175.24 562.75 ± 131.27 0.164 0.05
Energy balance (kcal/day) 159.89 ± 854.92 529.75 ± 1290.38 9.12 ± 652.53 0.187 0.05
MD adherence (0–14 range) 6.83 ± 1.75 6.76 ± 1.66 7.41 ± 2.00 0.442 0.02
Systolic Blood Pressure (mmHg) 116.38 ± 11.84 116.72 ± 6.25 109.44 ± 12.32 0.035 *& 0.09
Diastolic Blood Pressure (mmHg) 70.68 ± 11.12 68.89 ± 9.26 66.85 ± 8.87 0.466 0.02
Blood pressure recovery (ratio) 0.88 ± 0.20 0.83 ± 0.27 0.83 ± 0.31 0.731 0.01
Plasma glucose (mg/dL) 98.68 ± 11.61 101.56 ± 9.57 103.00 ± 9.25 0.376 0.03
Plasma triglycerides (mg/dL) 67.20 ± 23.09 71.36 ± 26.29 70.54 ± 24.94 0.822 0.01
Tumor necrosis factor-α (pg/mL) 8691.86 ± 9769.21 6489.78 ± 5639.46 11,644.02 ± 6755.80 0.083 0.07
Interleukin-6 (pg/mL) 609.51 ± 495.12 422.08 ± 292.73 428.72 ± 165.75 0.198 0.06
BM VO2max (mL · kg−1 ·min−1) 37.30 ± 13.15 42.25 ± 11.93 43.46 ± 9.40 0.189 0.05
LM VO2max (mL · kg−1 ·min−1) 18.05 ± 4.04 18.57 ± 5.27 19.47 ± 3.73 0.617 0.01
Absolute MFO (g ·min−1) 0.40 ± 0.17 0.35 ± 0.15 0.38 ± 0.16 0.493 0.02
R-MFO (mg ·kg−1 ·min−1) 7.48 ± 2.80 6.66 ± 3.04 7.11 ± 2.66 0.582 0.02
Clustered CMR (Z-score) 0.89 ± 3.64 0.73 ± 3.47 −0.65 ± 2.09 0.323 0.03
INFLAM-Clustered CMR (Z-score) 1.35 ± 3.01 −0.28 ± 3.54 −0.74 ± 1.80 0.172 0.08
N 23 33 18
Sex differences (p < 0.05) in the 1-way ANOVA appear in bold. * means significant differences between II and DD and & between II and
ID in the Bonferroni post-hoc comparison. Values are expressed as mean ± standard deviation. Abbreviations: d, Cohen’s d; MVPA,
Moderate to vigorous physical activity; MD, Mediterranean diet; BM, Body mass; LM, Lean mass; VO2max, Maximal oxygen uptake;
R-MFO, Maximal fat oxidation rate relativized to lean mass; CMR, Cardiometabolic risk; INFLAM-Clustered CMR, Cluster of CMR which
includes TNF-α and IL-6.
Table 3. Comparisons of the recesive model (DD vs. ID/II) in the analysed outcomes.
DD ID/II p d
Number of men/women 11/12 35/16 - -
Age (years) 23.57 ± 5.29 22.16 ± 3.65 0.188 0.33
Height (cm) 170.67 ± 10.32 172.83 ± 7.85 0.326 −0.25
Body Mass (kg) 79.71 ± 17.44 74.76 ± 15.05 0.217 0.31
Lean body mass (kg) 53.66 ± 8.20 54.71 ± 9.13 0.638 −0.12
Body fat (%) 27.29 ± 10.82 21.41 ± 8.96 0.017 0.61
Body Mass Index (kg ·m−2) 27.64 ± 7.38 24.98 ± 4.46 0.058 0.48
Waist circumference (cm) 86.78 ± 16.89 82.13 ± 13.54 0.226 0.32
Total MVPA (min/week) 501.55 ± 171.02 503.13 ± 165.67 0.971 −0.01
Energy balance (kcal/day) 159.89 ± 854.92 346.00 ± 1128.52 0.484 −0.18
MD adherence (0–14 range) 6.83 ± 1.75 6.98 ± 1.79 0.732 −0.09
Systolic Blood Pressure (mmHg) 116.38 ± 11.84 114.10 ± 9.47 0.382 0.22
Diastolic Blood Pressure (mmHg) 70.68 ± 11.12 68.15 ± 9.09 0.308 0.26
Blood pressure recovery (ratio) 0.88 ± 0.20 0.83 ± 0.28 0.427 0.20
Plasma glucose (mg/dL) 98.68 ± 11.61 102.07 ± 9.39 0.187 −0.33
Plasma triglycerides (mg/dL) 67.20 ± 23.09 71.07 ± 25.57 0.537 −0.16
Tumor necrosis factor-α (pg/mL) 8691.86 ± 9769.21 8207.86 ± 6447.65 0.804 0.06
Interleukin-6 (pg/mL) 609.51 ± 495.12 424.63 ± 249.00 0.071 0.54
BM VO2max (mL · kg−1 ·min−1) 37.30 ± 13.15 42.69 ± 11.01 0.072 −0.46
LM VO2max (mL · kg−1 ·min−1) 18.05 ± 4.04 18.89 ± 4.76 0.468 −0.18
Absolute MFO (g ·min−1) 0.40 ± 0.17 0.36 ± 0.15 0.337 0.24
R-MFO (mg ·kg−1 ·min−1) 7.48 ± 2.80 6.83 ± 2.89 0.367 0.32
Clustered CMR (Z-score) 0.89 ± 3.64 0.27 ± 3.12 0.469 0.19
INFLAM-Clustered CMR (Z-score) 1.35 ± 3.01 −0.43 ± 3.03 0.066 0.59
N 23 51
Sex differences (p < 0.05) in the Student t test appear in bold. Values are expressed as mean ± standard deviation. Abbreviations: d, Cohen’s
d; MVPA, Moderate to vigorous physical activity; MD, Mediterranean diet; BM, Body mass; LM, Lean mass; VO2max, Maximal oxygen
uptake; R-MFO, Maximal fat oxidation rate relativized to lean mass; CMR, Cardiometabolic risk; INFLAM-Clustered CMR, Cluster of CMR
which includes TNF-α and IL-6.
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One of the main aims of this study was to analyze the sex and genotype interaction.
In this sense, there was a sex × genotype interaction in R-MFO with body fat percentage
as covariable (F(2,66) = 3.35; p = 0.041; ηp2 = 0.092) (Figure 1A). Similarly, attending the
recessive model (DD vs. ID/II), a significant interaction between sex and genotype was
found in absolute MFO (F(2,69) = 3.10; p = 0.049; ηp2 = 0.054) and R-MFO (F(2,69) = 3.90;
p = 0.048; ηp2 = 0.065). Specifically, the DD polymorphism had higher R-MFO values
than ID/II polymorphisms in men (8.4 ± 3.0 vs. 6.5 ± 2.9 mg/kg/min), while the ID/II
polymorphisms showed higher R-MFO values than DD polymorphism in women (6.6 ±
2.3 vs. 7.6 ± 2.6 mg/kg/min) (Figure 1B). The sex × genotype analyses did not show other
statistically significant interactions in the registered variables.
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4. Discussion
Our results highlighted that some CMR-related outcomes presented differences accord-
ing to the ACE I/D gene polymorphism in young adults. Similarly to previous research [6],
in our participants the II genotype presented lower body fat percentage and lower SBP than
DD and ID genotypes. Accordingly, previous studies have found associations between
ACE gene I/D polymorphism and CMR, where the DD polymorphism presented higher
metabolic disturbances than ID/II polymorphisms partly due to a greater activity level
of ACE protein [24,25]. Therefore, those subjects with II genotype seem to have a lower
CMR and lower cardiovascular events than DD genotype [10]. These results support that
the ACE gene I/D polymorphism partly influences cardiometabolic health and adiposity,
although it should not be forgotten that genetics does not fully determine the phenotype of
individuals, since environmental factors also play an important role.
Regarding the study of relevant factors in modulating the relationship of genotype
and health outcomes, it becomes important the analysis of sex differences. In this line, the
main finding of the present study was that there is a sexual dimorphism in the influence
of ACE I/D gene polymorphism on MFO. Additionally, it has been previously reported
a sex-spe ific ffect of ACE gene I/D polymorphism on other CMR parameters, such as
bl od pre sure and hypertension [26,27]; however, our study only reported significant
sex*genotype interactions in MFO, the main variable regarding metabolic flexibility.
Under our t is is the first study that determines the influenc of ACE gene
I/D polymorphism on MFO. Specifically, our st dy described that MFO was higher n DD
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genotype compared with ID/II genotype for men, while it was higher in ID/II genotype
compared with DD genotype for women. Therefore, the influence of the ACE I/D gene
polymorphism on cardiometabolic flexibility and the ability to oxidize fats during exercise
may be sex-dependent, and seems to be independent of CRF (VO2max). According to a
previous study [28], which analyzed the influence of androgen receptor CAG and GGN
repeat polymorphisms on MFO, the mentioned sexual dimorphism could be explained by
hormonal differences between men and women; however, the study was performed only
in young males, highlighting the interest of the present study.
The mechanisms that can explain these sex differences have not been fully established.
However, it has been previously shown that estrogens may protect female rats against
hypertension by amplifying the vasodilator contributions of Ang-(1–7) and reducing
formation of AngII [29–31]. Higher levels of Ang-I and Ang-II were found in DD females
in a cohort of healthy individuals [32]. Ang-II hormone stimulates vasoconstriction which
could reduce the arrival of oxygen and fatty acids from adipose tissue to the skeletal muscle.
In fact, it has been reported that high levels of Ang-II reduce the sympatholysis observed
during physical exercise, which could explain lower fat oxidation in women belonging to
the DD genotype of our study.
These results could be applied to healthy lifestyle interventions aimed at preventing or
reducing overweight and obesity. In this line, most interventions are focused on increasing
physical activity or on reducing calorie intake through diet or on increasing physical activity
and exercise. However, the adherence to these interventions sometimes is scarce. Thus, the
possible differences between genotypes could help to individually adjust physical activity
and dietary programs.
Regarding physical activity and exercise, a review concluded that individuals with at
least one ACE D allele had significantly better functional performance after exposure to
higher levels of physical activity or after an exercise intervention than those homozygous
for ACE I allele [33]. However, other studies have not found differences of physical activity
levels according to the ACE I/D gene polymorphism, similarly to our findings [34]. Thus,
currently there is no clear consensus on whether the insertion (I) polymorphism or the
deletion (D) polymorphism could affect cardiometabolic flexibility and aerobic capacity.
Some reviews [35,36] have concluded that the limited number of genetic variants studied in
small and heterogeneous cohorts is a common limitation in the field of exercise genomics.
Moreover, these discrepancies can be due to the fact that there is a sexual dimorphism in
the influence of ACE I/D gene polymorphism on MFO. Therefore, future interventional
studies should consider this aspect to elucidate the ACE-polymorphism specific responses
to physical exercise.
Related to dietary interventions, interestingly, a previous study in obese women [15]
showed a higher reduction of body fat in the II/ID genotype compared with the DD
genotype after a calorie-restricted dietary intervention with statistically significant differ-
ences in resting fat oxidation. However, in our study, caloric energy balance and dietary
patterns (adherence to Mediterranean diet) was not determined by the ACE I/D gene
polymorphism. It should be noted that no previous studies have investigated the influence
of ACE gene I/D polymorphism on energy balance and adherence to Mediterranean diet.
Therefore, the present study offers novel information indicating that dietary patterns are
probably largely determined by environmental factors in young adults; however, as it was
mentioned before, adiposity differed between groups.
This study is not exempt from critics and limitations. Firstly, the sample size of
this cross-sectional study is scarce to raise conclusions (e.g., there are only 6 women in
the II group). Secondly, the population is young and, despite obesity, healthy; therefore,
extrapolation of results should take this into account. Future studies including a higher
sample with greater heterogeneity in CMR, physical activity and CRF parameters and
longitudinal designs are warranted. Finally, the measurement of body composition by
bioimpedance instead of using another more precise method like Dual Energy X-ray
Absorptiometry (DXA) is also a limitation. Notwithstanding, the determination of MFO
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and CRF in a controlled situation (with a laboratory test, gas analyzer, etc.) and the number
of registered outcomes bring strengths to the design.
5. Conclusions
In conclusion, ACE I/D polymorphism is apparently associated with higher adiposity
and BP, but not with CRF, diet and physical activity. Moreover, our study highlighted
that there is a sexual dimorphism in the influence of ACE I/D gene polymorphism on
R-MFO. This fat oxidation capacity was higher in DD genotype than in II/ID genotype in
men; while R-MFO was higher in II/ID genotype than in DD one in women. Therefore,
physical exercise interventions that are performed at this intensity (low-intensity aerobic
training) can have different responses in a young adult population according to the ACE
I/D polymorphism and sex. Nevertheless, more studies are needed in order to deepen in
the research of ACE gene I/D polymorphism and its relationship with health.
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